Notícias

In today’s global franchising landscape, a franchise in the human and veterinary health sector stands out with excellence: Biomagistral Farmacêutica. This mixed compounding pharmacy network operates in both human and veterinary compounding, including vaccines, all under the same operation. With franchisees reaching profit margins as high as 35%, the company has become a favorite among investors looking to enter a solid market like the global veterinary health market.

The multinational is revolutionizing the global pet market by compounding any type of veterinary treatment, from nutritional supplements to controlled medications for pain management, in palatable formats tailored not only to the flavor preferences of the animal but also to the specific format, breed, and dosage according to the animal’s weight. This means that if a medication is made for a 1kg Chihuahua, it will be compounded into a biscuit suitable for its bite size, and in the exact dosage needed for a 1kg animal. Meanwhile, the same medication can be compounded for a 40kg Golden Retriever in the proportional dosage. The same applies to other species, such as cats, which are notoriously difficult to medicate. In these cases, the company provides medications in salmon-flavored treats, sardine pastes, oral films, and more. Large animals are also included in the product mix. Horses, for example, receive their treatments in sugar cubes, which they love.

Providing this ease and precision in animal treatment not only wins over pet owners but also veterinarians, who see significant improvement in treatment outcomes. When it’s easier to medicate, adherence to treatment is consistent from start to finish, simplifying the owner’s life and eliminating the stress of medication time. It also ends the irregular routine of cutting pills in a blind attempt to reach the correct dosage for pets.

Another key differentiator for the company is the compounding of palatable cannabidiol, which has been widely used in veterinary health, especially in the management of chronic pain and epilepsy.

Founded in 1979, the company now celebrates 45 years in the health market in 2024 and has established itself as the global leader in the sector, aggressively expanding its operations in the U.S. market. The brand is already present in five U.S. states: Texas, California, Florida, New York, and Michigan, with the opening of 37 stores, 15 of which are in New York City.

João Roberto Tondato, president of the Biomagistral Farmacêutica network, explains the business’s success: "The health sector, in itself, is an excellent business, which doesn’t face crises and always remains stable and growing. Our operations have solidified in the billion-dollar pet market with reduced input costs, standardized and simplified operations, and, in addition, our profitability reaches 25 to 35% net profit. We are confident in offering a product with high technology and innovation, with no competition in the veterinary health sector."